⚕️ The information below is for educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Weight gain from antipsychotic medications is one of the most under-addressed challenges in Indian psychiatry. Millions of patients on olanzapine (Olanz, Olanex), clozapine, quetiapine (Qutipin, Seroquel), or risperidone gain significant weight — often 10–25 kg — in the first year of treatment. This weight gain worsens metabolic health, increases cardiovascular risk, undermines medication adherence, and significantly affects quality of life.
GLP-1 medications — semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) — have emerged as a promising solution for this problem. Landmark clinical evidence now supports their use in patients with antipsychotic-induced weight gain, but the approach must be thoughtful, coordinated between psychiatrist and endocrinologist, and tailored to the Indian healthcare context.
Consult your healthcare provider before starting any medication and specifically discuss both your psychiatric and metabolic management with the doctors involved in your care.
India has a large and growing population of patients on antipsychotic medications:
Indian patients face compounded metabolic risk because:
Different antipsychotics cause weight gain through different mechanisms:
Histamine H1 receptor blockade: Olanzapine and clozapine are potent H1 blockers. Blocking histamine in the hypothalamus increases appetite and reduces satiety — the same mechanism that makes old antihistamines (like promethazine) sedating and appetite-stimulating.
Serotonin 5-HT2C receptor blockade: Blocking this receptor increases appetite and reduces energy expenditure. Olanzapine, clozapine, and quetiapine all have significant 5-HT2C activity.
Dopamine D2 receptor blockade: While the primary target of antipsychotics, D2 blockade in the hypothalamus may contribute to metabolic dysregulation.
Direct insulin resistance: Some antipsychotics, particularly clozapine and olanzapine, appear to cause insulin resistance independently of weight gain — directly impairing glucose metabolism.
| Antipsychotic | Indian Brands | Average Weight Gain (1 year) | Metabolic Risk |
|---|---|---|---|
| Clozapine | Sizopin, Clozapin | 8–15 kg | Very High |
| Olanzapine | Olanz, Olanex, Oliza | 6–12 kg | Very High |
| Quetiapine | Qutipin, Seroquil | 4–8 kg | High |
| Risperidone | Risdone, Risperdal | 2–4 kg | Moderate |
| Aripiprazole | Arip MT, Abilify | 1–2 kg | Low |
| Ziprasidone | Zipsydon | 0–1 kg | Low |
Note: Individual variation is significant. These are averages from clinical trials.
Yes — and the evidence is robust and growing.
The OVERCOME Trial (2023): This randomised controlled trial specifically examined semaglutide (2.4 mg weekly, the Wegovy dose) in patients with schizophrenia spectrum disorders on antipsychotics. Key findings:
Additional evidence:
This is the most important step. In India:
At minimum, obtain before starting GLP-1 therapy:
For patients with type 2 diabetes or prediabetes AND antipsychotic weight gain:
For patients with obesity from antipsychotics WITHOUT diabetes:
More frequent monitoring is recommended in psychiatric patients on GLP-1 therapy:
Clozapine deserves special attention because:
Mistake 1: Starting GLP-1 without informing your psychiatrist Changes in appetite, nausea, and weight from GLP-1 can be confused with psychiatric symptoms or medication changes. Your psychiatrist must know.
Mistake 2: Escalating GLP-1 dose too quickly in psychiatric patients Standard dose escalation is already slow, but psychiatric patients may benefit from an even more gradual approach — staying at each dose level for 8 weeks rather than 4.
Mistake 3: Stopping psychiatric medication due to improved mood or weight Weight loss and metabolic improvement can feel transformative. Some patients attempt to stop antipsychotics, believing they no longer need them. This is dangerous. Psychiatric medications must only be changed under psychiatrist supervision.
Mistake 4: Not monitoring for worsening psychiatric symptoms Most patients on GLP-1 experience no psychiatric side effects. However, very occasionally, altered appetite and metabolism can destabilise mood. Alert your psychiatrist immediately if you experience worsening depression, anxiety, agitation, or psychotic symptoms after starting GLP-1.
Mistake 5: Choosing aripiprazole switch over GLP-1 without medical advice Switching from olanzapine to a more metabolically neutral antipsychotic (like aripiprazole) is another approach to antipsychotic weight gain. This is sometimes preferable to adding GLP-1. Discuss both options with your psychiatrist — the decision depends on your psychiatric stability and history.
Contact your psychiatrist or endocrinologist immediately if:
Q: Will semaglutide or tirzepatide reduce the effectiveness of my antipsychotic? No pharmacokinetic interaction between GLP-1 medications and common antipsychotics (olanzapine, clozapine, risperidone, quetiapine) has been established. GLP-1 medications do not appear to reduce antipsychotic blood levels or efficacy.
Q: My psychiatrist is not familiar with GLP-1 medications. What should I do? Bring a printed summary of the OVERCOME trial to your appointment. Suggest that your psychiatrist communicate with an endocrinologist. In India, the Indian Psychiatric Society and the Endocrine Society of India are both aware of this emerging treatment area.
Q: Can GLP-1 medications cause psychosis or worsen schizophrenia? The OVERCOME trial specifically found no worsening of psychiatric symptoms. Dopaminergic activity is not a mechanism of GLP-1 medications. However, any significant physiological change can theoretically affect mental state — close monitoring is sensible.
Q: My family member is on clozapine and has gained 20 kg. What should we do? Speak to the treating psychiatrist first. Request a metabolic health assessment. Ask for a referral to an endocrinologist who is aware of the antipsychotic metabolic syndrome. GLP-1 medications may be appropriate but require coordination between the two specialists.
Consult your healthcare provider before starting any medication. Antipsychotic-induced weight gain is a serious medical problem that deserves the same attention as the psychiatric condition itself — and GLP-1 medications offer real, evidence-based help for this often-overlooked complication.
